Adam Shilling, Ph.D.


Vice President of Early Development and Regulatory Affairs

Adam Shilling, Ph.D. is Vice President Early Development and Regulatory Affairs at Prelude Therapeutics with 20 years of pharmaceutical experience spanning all phases of clinical and preclinical development. Prior to joining Prelude, Adam was Executive Director of Global Regulatory Affairs at Incyte where he was the global regulatory lead for the GVHD franchise and JAK1 programs. Adam led the NDA submission and approval of Jakafi in acute GVHD and contributed to the development and NDA approvals for Jakafi in myelofibrosis and polycythemia vera and Olumiant in rheumatoid arthritis. Prior to Incyte, Adam was Principal Research Scientist at Wyeth, contributing to programs in infectious diseases, women’s health, and neuroscience, including the NDA for Pristiq in major depressive disorders. He received his BS in Marine Biology at LIU Southampton and PhD in Toxicology at Oregon State University.